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Author
(year)
Total no. of pa
(localised)
Lee (1995) [8] 40
Ahmad (2002) [6] 60 (38)
Choi (2014) [9] 53 (42)
Thampi (2014) [10] 256 (188)
Longhi (2017) 266 (211)
ESOS Z extraskeletal osteosarcoma; O
disease free survival.Patients and methods: Members of the European Musculoskeletal Oncology Society (EMSOS)
submitted institutional data on patients with ESOS.
Results: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS
centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients
with localised disease, 211 (98%) underwent surgery (R0 Z 70.6%, R1 Z 27%). Five-year
overall survival (OS) for all 266 patients was 47% (95% CI 40e54%). Five-year OS for
metastatic patients was 27% (95% CI 13e41%). In the analysis restricted to the 211 localised
patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI
44e59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35e51%). One hundred
twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients
(37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type
chemotherapy versus soft tissue sarcoma-type (doxorubicin  ifosfamide) regimens. For the
211 patients in complete remission after surgery, patient age, tumour size, margins and
chemotherapy were positive prognostic factors for DFS and OS by univariate analysis.
At multivariate analysis, patient age (40 years versus >40 years) (P Z 0.05), tumour size
(PZ 0.0001) and receipt of chemotherapy (PZ 0.006) were statistically significant prognostic
factors for survival.
Conclusion: Patient age and tumour size are factors influencing ESOS prognosis. Higher sur-
vival was observed in patients who received perioperative chemotherapy with a trend in
favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide
and cisplatin.
ª 2017 Elsevier Ltd. All rights reserved.1. Introduction
First reported in 1941, extraskeletal osteosarcoma
(ESOS) is a rare mesenchymal tumour arising in soft
tissue accounting for 1% of all soft tissue sarcomas and
4% of all osteosarcomas [1e3]. Several retrospective
series have been reported, mostly with less than 50 pa-
tients. The largest series are shown in Table 1. Median
age at diagnosis is in the fifth and sixth decade of life. In
children, ESOS are much rarer than skeletal osteosar-
coma [11]. Males prevail in all but one cohort. Aetiology
is unknown, although 5e10% occur after radiotherapy
(RT) and preceding trauma is reported in 12e13% [7].
An association with previous myositis ossificans has also
been postulated [12].
ESOS usually occurs as a slow growing mass with a
longer interval between symptom onset and diagnosis
compared to skeletal osteosarcoma (median 6 versus 2
months) [4e8,14]. Common sites are limbs,tients Outcome
5-year OS 37%
5-year DFS 46%
(localised)
3-year OS 61%
(localised)
5-year OS 37%
(47% in localised)
5-year OS 47%
(51.4% in localised)
S Z overall survival; DFS =retroperitoneum and chest wall [7], but 50 cases arising
in the breast have been described [15]. These must be
distinguished from matrix-producing epithelial breast
carcinomas. Recommended criteria for ESOS of the
breast include absence of an epithelial component and
presence of malignant osteoid [15,16]. Histologically
ESOS presents similar characteristics to those of skeletal
osteosarcoma with a differing proportion of osteoid and
cartilaginous and fibrous tissue [13]. It is high grade
though exceptionally may be well differentiated [1].
ESOS relapse rate is over 75% [13]. Distant metas-
tases occur most frequently in lungs, lymph nodes and
bone [7].
Surgical resection is the standard treatment. ESOS
are considered poorly responsive to chemotherapy:
Ahmad et al. [6] reported only 19% response (complete
remission [CR]þ partial remission [PR] to doxorubicin-
based chemotherapy and 13% to cisplatin-based
chemotherapy. However, because of the perceived sim-
ilarities to skeletal osteosarcoma, the role of chemo-
therapy is debated.
This retrospective study, performed under the aus-
pices of EMSOS, aimed to improve knowledge on the
natural history of ESOS, identify prognostic factors and
inform on the role of chemotherapy treatment.2. Patients and methods
A request was sent to EMSOS members to participate in
the study with study information available on the soci-
ety website (www.emsos.org). All participating centres
obtained ethical approval. All centres were provided
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data.
From March 2014 to December 2015 data for 274
patients treated from 1981 to 2014 from 16 centres or
cooperative groups were submitted for analysis. For this
study we accepted a time lapse of 33 years due to rarity
of the disease and considering that not many changes
occurred in this period for ESOS treatment. Analyses
were performed by descriptive statistics. Median follow
up for the 266 patients was 22.5 months (range
1e384 months).
Overall survival (OS) was calculated from diagnosis
to death or last follow up, disease-free survival (DFS)
was calculated from date of surgery to relapse/progres-
sion or last follow up by the KaplaneMeier method.
The time scale was extended to the last follow up if none
of these events were observed. Log-rank test was used to
compare survival curves for the different subgroups of
patients. Statistical significance of each variable was
then tested by multivariate analysis using the stepwise
model and Cox regression analysis. Osteosarcoma-type
chemotherapy corresponds to the multidrug regimen
similar to that used for bone osteosarcoma with
cisplatin, doxorubicin, ifosfamide, methotrexate and
sometimes etoposide. Soft tissue sarcoma-type chemo-
therapy corresponds to a regimen similar to that used
for soft tissue sarcomas (an anthracycline with or
without ifosfamide).3. Results
Two hundred sixty-six patients had adequate data for
analysis. Patient characteristics are reported in Table 2.
There was a higher incidence of male gender
(M:FZ 1.5:1). Median age was 57 years (range, 12e91).
The median interval from symptom onset to diagnosisTable 2
Patient characteristics; all 266 pts (left) and 211 pts with localised
ESOS (right).
All patients (266) Pts with localised
disease (211)
Median age years 57 (12e91) 57 (12e91)
Gender
- Male 162 M:F Z 1.5:1 128 M:F Z 1.5:1
- Female 104 83
Stage
- Localised 216 (80.8%) 211
- *Metastatic 50 (18.7%) e
Site of primary tumour
- Extremity 221 (83%) 180 (85.7%)
- Non-extremity 45 (16.9%) 31 (14.3%)
Chest 25 17
Abdomen 8 3
Viscera 6 5
Breast 6 6
ESOS Z extraskeletal osteosarcoma; Pts Z patients; *Metastatic at
diagnosis.was 5 months (range 0e130 months) with some cases of
very late diagnosis. Median tumour size was 10 cm
(range 2e50 cm). Histologic subtype distribution was
similar to that of skeletal osteosarcoma [1]. Most cases
were categorised as high grade osteosarcoma without
specification of subtype. Three patients had a previous
diagnosis of myositis ossificans in the site where ESOS
occurred. Twelve patients had 13 different previous
malignancies. ESOS was a radiotherapy-induced sec-
ondary malignancy in 5 of these 12 patients: 1 non-
Hodgkin lymphoma, 1 fibrosarcoma, 1 rhabdomyosar-
coma and 2 Ewing sarcomas, after a mean interval of
17.7 years (7e38 yrs). Five-year OS for the 266 patients
was 47% (95% CI 40e54%) and 51.4% (95% CI
44e59%) for the 211 patients with localised disease
(P < 0.0001) after surgical excision (Fig. 1).
Six patients developed a second malignancy after
ESOS (two kidney carcinoma, one bladder carcinoma,
one prostate cancer and two acute myeloid leukaemia
[AML]). The 2 patients (15-year old male and 54-year
old female) who developed AML received
osteosarcoma-type chemotherapy and no RT and AML
was probably in correlation with chemotherapy. The
other tumours occurred in patients over 70 years of age.
The 2 patients with secondary kidney carcinoma and the
patient with prostate cancer received only chemo-
therapy. The patient of 73 with ESOS of shoulder
treated with local RT developed a bladder cancer 13
years later. So apart from AML, the other secondary
cancers could be related more to age of patients.3.1. Patients with metastases
Fifty patients had metastases at diagnosis: median age
58.5 years (range, 13e87 years), 32 male and 18 female,
40 patients had one metastatic site, ten had multiple
sites. Lung metastases were reported in 42/50 patients,
bone in four, lymph nodes in six, abdominal metastasesFig. 1. 5-year overall survival of localised versus metastatic
extraskeletal osteosarcoma (P < 0.0001).
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specified), liver metastases in two and brain metastases
in 1 patient.
Chemotherapy was administered in 36 of the 50 met-
astatic patients at presentation. 28/36 (77.7%) received
an osteosarcoma-type regimen: five received doxor-
ubicinecisplatin, 11 doxorubicinecisplatineifosfamide,
nine doxorubicinecisplatineifosfamideemethotrexate,
two doxorubicinecisplatineifosfamideeetoposide and
one doxorubicinecisplatineifosfamideemethotrexatee
etoposide. Eight patients received a soft tissue sarcoma-
type scheme: four a combination of
doxorubicin þ ifosfamide, three doxorubicin alone and
one only high dose ifosfamide. RT was given to 14 pa-
tients, in 11 it was associated with chemotherapy. Two
patients received only best supportive care. Thirty-three
of 50 patients were already dead at the onset of the
study, with a median follow up of 19 months (range,
1e142 months), the 5-year OS for the 50 metastatic
patients was 27% (95% CI 13e41%).
3.2. Patients with localised disease
Of the 216 patients with localised disease at diagnosis,
211 underwent surgical resection of the primary tumour,
in 5/216 (2.3%) no surgery was performed (primary site:Table 3
5-year DFS and 5-year OS in 211 patients with localised ESOS.
No. of Pts
211
Gender Male 128 (60.6%)
Female 83 (39.3%)
Age 18 years 16 (7.5%)
19e40 years 32 (15.1%)
41e65 years 98 (46.4%)
>65 years 65 (30.8%)
Size 5 cm 42 (19.9%)
5e10 cm 80 (37.9%)
>10 cm 72 (42.1%)
Unknown 17
Margins R0 149 (70.6%)
R1 57 (27%)
Unknown 5
RT Yes 80 (37.9%)
No 128 (60.6%)
Unknown 3
Treatment Surgery alone 46 (21.8%)
Surgery þ CT 83 (39,3%)
Surgery þ RT 43 (20.3%)
Surgery þ CT þ RT 37 (17.5%)
Unknown 2
Chemo Yes 121 (57.3%)
No 86 (40.7%)
Unknown 4
Chemo type Osteo-type 69 (57.5%)
STS-type 43 (35.8%)
Unknown 9
ESOS Z extraskeletal osteosarcoma DFS Z disease-free survival; OS Z o1 neck, 1 chest, 1 thigh, 2 pelvises). Of these patients,
three received only local palliative RT, the other two
received chemotherapy alone. Data of 211 localised
patients are reported in Table 3.
Forty-six (21.8%) had surgery alone, 43 (20.3%) had
surgery þ RT, 83 (39.3%) had surgery þ
chemotherapy and 37 (17.5%) received surgery þ
RT þ chemotherapy. In two cases treatment was un-
known. Surgical margins were reported as R0 in 149
(70.6%) patients, R1 in 57 (27%) and unknown in five.
In this group of 211 patients with resected localised
disease, 5-year OS and 5-year DFS were 51.4% (95% CI
44e59%) and 43% (95% CI 35e51%), respectively
(Fig. 2). One hundred twenty-one of 211 (57.3%) pa-
tients with localised disease were alive at time of data
lock; 77/90 (85.5%) died of ESOS; 13 patients died of
causes unrelated to ESOS treatment (12 of whom had no
recurrence reported): 2/13 died of a haematologic second
malignancy (one AML and one myelodysplastic syn-
drome (MDS) which progressed to AML). The 2
patients who developed an AML received chemotherapy
osteosarcoma-type and no RT. One case was a 15-year
old male, who after 2 years from diagnosis of ESOS
developed AML, the other was a 54 year old female,
who developed a MDS 3 years after ESOS treatment
and after another 4 months MDS turned into AML.5-year DFS (95% CI) 5-year OS (95% CI)
43% (35e51) 51.4% (44e59)
40% (31e50) 48% (39e58)
46% (33e59) 56.5% (44e69)
P Z 0.2 P Z 0.9
67% (43e91) 58% (32e84)
65% (46e84) 71% (52e89)
45% (33e56) 57% (46e68)
18% (6e31) 29% (16e43)
P Z 0.0003 P Z 0.0001
74% (59e90) 78% (64e92)
34% (22e45) 46% (34e58)
30% (16e44) 34% (21e47)
P Z 0.0001 P Z 0.0001
51% (42e61) 58% (48e67)
24% (10e37) 37% (23e52)
P Z 0.002 P Z 0.006
46% (36e56) 52% (40e65)
40% (28e52) 52% (42e62)
P Z 0.3 P Z 0.5
26% (10e42) 37% (21e53)
56% (44e68) 60% (48e73)
27.5% (12e43) 40% (24e56)
52% (35e69) 64% (46e81)
P Z 0.02 P Z 0.002
55% (45e65) 62% (51e72)
27% (16e38) 38% (26e49)
P Z 0.003 P Z 0.0002
62% (49e75) 65% (52e79)
48% (32e64) 59% (42e75)
P Z 0.05 P Z 0.08
verall survival.
0.00
25.00
50.00
75.00
100.00
0 100 200 300 400
months
only surgery
surgery+radio
surgery+chemio
surgery+radio+chemio
only surgery 46 pts (21.8%)
surgery+RT 43 pts (20.3%)
surgery+CT 83 pts (39.3%)
surgery+RT+CT 37 pts (17.5%)
Fig. 2. 5-year overall survival and treatment (P Z 0.002).
Fig. 3. 5-year overall survival for chemotherapy versus no
chemotherapy (P Z 0.0002).
Table 4
Distribution of treatment in 211 patients with localised ESOS ac-
cording to age, margins, size.
Surgery
(%)
Surgery and
RT (%)
Surgery þ
Chemo  RT (%)
P value
Age P Z 0.0001
18 6.2 6.2 87
19e40 9.3 12.5 78
41e65 17.3 13.2 69
>65 39.6 39.6 20.6
Margins P Z 0.01
R0 20.9 16.2 62
R1 26.7 32.1 41
Size P Z 0.69
5 cm 23.8 26.1 50
5e10 cm 18.8 24 56.9
>10 cm 23.9 16.9 59.1
ESOS Z extraskeletal osteosarcoma; RT Z radiotherapy.
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patients. In 55 (68.7%) RT was administered post-
operatively, in 5 (6%) preoperatively, in 3 (4%) RT was
palliative, in the remaining 17 (21%) timing of RT was
unknown. Median dose was 58 Gy (36e79 Gy).
Chemotherapy was administered in 121 (57.3%) pa-
tients. In 32/121 as neoadjuvant (preoperative), in 75 as
adjuvant and in the remaining 14 it was not specified an
osteosarcoma-type regimen of chemotherapy was
administered in 69 (57.5%) patients. A soft tissue-type
regimen was administered to 43 patients (35.8%). In the
remaining 9 patients (7.4%) the type of chemotherapywas
unknown. All together 68/69 received doxorubicin, 65/69
received cisplatin; 58/69 received ifosfamide and 27
received methotrexate. The combinations were the
following: 10 patients received cisplatin and doxorubicin,
28 doxorubicinecisplatineifosfamide, 23 doxor-
ubicinecisplatineifosfamideemethotrexate, four dox-
orubicinecisplatineifosfamideemethotrexate-etoposide
and carboplatin and three received VIDE (vincristine,
ifosfamide, doxorubicin, etoposide) chemotherapy.
Median number of cycles for patients treated with
osteosarcoma-type chemotherapy was 5 (range 2e20).
Thirty-six patients treated with soft tissue sarcoma-
type chemotherapy received a combination of an anthra-
cycline associated with ifosfamide. Only 5 patients
received anthracycline as single agent, 2 received etoposide
and ifosfamide without anthracycline. The median num-
berof chemotherapy cycles perpatientwas 3 (range1e12).
Table 3 reports the 5-year DFS and OS according to
patient characteristics and treatment. Five-year DFS
and OS were significantly better (P Z 0.003 and
P Z 0.0002, respectively) in patients selected to receive
chemotherapy (Fig. 3).
3.3. Distribution of treatment according to patient age,
tumour margins and size
These data are reported in Table 4. Chemotherapy was
given to 52.3% patients with tumours <5 cm, in 57.5% intumour 5e10 cm and in 61.3% when the tumour was
>10 cm (P Z 0.64). Chemotherapy was administered
more frequently in patients younger than 65 years
(P Z 0.0001). The use of chemotherapy in tumours
>5 cm was a significant prognostic factor for 5-year
DFS (Fig. 4). Median DFS of patients who received
an osteosarcoma-type regimen was 31.2 months (2e184)
compared to 14.9 months (2e384) of those who received
an soft tissue sarcoma (STS) type chemotherapy
(P Z 0.003). Patients treated with adjuvant
osteosarcoma-type chemotherapy reported a 5-year
DFS of 62% (95% CI 49e75%) versus 48% (95% CI
32e64%) in STS-type chemotherapy with a trend of
statistical significance in favour of osteosarcoma-type
chemotherapy (P Z 0.05) (Fig. 5). There was no dif-
ference in choice of administration of RT according to
tumour size or surgical margins.
3.4. Relapse
104/211 (49.2%) patients relapsed: 52 relapsed locally, 88
had distant metastases, 36 relapsed both locally and
Fig. 4. 5-year disease-free survival and size (P Z 0.0002).
0.00
25.00
50.00
75.00
100.00
0 100 200 300 400
months
STSlike
osteolike
STS-type 43 pts (35.8%)
Osteo-type 69 pts (57.5%) 
Fig. 5. 5-year disease-free survival and type of chemotherapy:
osteosarcoma-type versus soft tissue-type chemotherapy
(P Z 0.05).
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time to relapse was 12 months (1e185), median time to
local relapse was 13 months (2e116) and median time to
distant metastases was 11 months (2e185). Twelve pa-
tients had more than one distant metastatic site. Sites of
metastases were: lung in 64 patients, bone in 7, lymph
node in 5, soft tissue in 4, brain in 3, liver in 2, abdomen
in 2 and breast in 1.Table 5
Radiotherapy and local relapse.
Radiotherapy # Patients N
No RT in tumours >5 cm 87 5
Yes RT in tumours >5 cm 61 5
No RT in tumours >10 cm 40 2
Yes RT in tumours >10 cm 29 2
No RT in tumour margin R1 32 2
Yes RT in tumour margin R1 29 1
No RT in R0 only T > 5 cm 61 4
Yes RT in R0 only T > 5 cm 37 3
No RT in R1 only T > 5 cm 26 1
Yes RT in R1 only T > 5 cm 24 1
RT Z radiotherapy; T Z tumour; R0 and R1 margin according to UnionFor local relapse 22/52 patients received surgery
alone, six received surgery þ RT, six received
surgery þ chemotherapy, 1 surgery þ RT þ chemo-
therapy, 2 chemotherapy alone and 3 as palliative
treatment. In 12 patients treatment was not reported.
Treatment for distant relapse was unknown in 27/88
cases, treatment was surgery alone in 18, chemotherapy
alone in 16, surgery þ chemotherapy in ten,
surgery þ RT in four, chemotherapy þ RT in three and
best support in ten.
For the few patients with clinical data after local or
distant relapse the majority received gemcitabine-based
chemotherapy which is used in STS and as well in
osteosarcoma.
A further subanalysis of local relapse free survival
(LRFS) of the 31/52 patients with local relapse as only
site or first site of relapse (6 months before any further
relapse) showed a 5-year LRFS of 77% (95% CI
69e85%). Positive prognostic factors for LRFS were:
margins (P Z 0.05) and chemotherapy (P Z 0.04). At
multivariate analysis chemotherapy was the most
important prognostic factor for LRFS (P Z 0.004), RT
(P Z 0.07) was not significant.
Distant metastases free survival (DMFS) on 78 pa-
tients with distant metastases as unique or first site of
relapse had a 5-year DMFS of 55% (95% CI 47e64%).
Significant prognostic factors were size (P Z 0.002),
margins (PZ 0.004) and chemotherapy (PZ 0.004). At
multivariate analyses only size (P Z 0.003) and
chemotherapy (P Z 0.001) were significant.
All these results should be taken cautiously because
the cohort is small and heterogeneous.
3.5. Radiotherapy and local relapse (Table 5)
Local relapse rate was not statistically different for pa-
tients who received RT (P Z 0.7). RT decreased the
incidence of local relapse for patients with tumour
>5 cm (P Z 0.054) and in patients with tumour >5 cm
and R0 margins: local relapse occurred in 17/61 (28%) in
the no RT group versus 4/37(11%) in the RT group
(P Z 0.05). For patients with tumour >5 cm and R1
margins no statistically significant difference waso local relapse Local relapse P value
9 (68%) 28 (32%) 0.054
0 (82%) 11 (18%)
8 (70%) 12 (30%) 0.1
5 (86%) 4 (14%)
0 (62.5%) 12 (37.5%) 0.9
8 (86%) 11 (38%)
4 (72%) 17 (28%) 0.05
3 (89%) 4 (11%)
5 (58%) 11 (42%) 0.3
7 (71%) 7 (29%)
for International Cancer Control (UICC) margin classification.
Table 6
Multivariate analysis.
Variable Relative risk P value
Age
40 yrs 1
>40 yrs 0.49 (95% CI 0.25e0.99) P Z 0.05
Size
>10 cm 1
10 cm 0.38 (95% CI 0.24e0.6) P Z 0.0001
Chemotherapy
Yes CT 1
No CT 1.92 (95% CI 1.2e3.1) P Z 0.006
Margins
R1 1
R0 0.65 (95% CI 0.4e1.1) P Z 0.075
A. Longhi et al. / European Journal of Cancer 74 (2017) 9e16 15observed for local relapse in relation to RT (P Z 0.3).
Seen the paucity of patients who underwent adjuvant
RT its role in ESOS must be further examined.
At univariate analysis for 5-year DFS the significant
prognostic factors were size, age, margins, chemo-
therapy and type of chemotherapy for the 211 patients
with localised resected disease. Size, age, margins and
chemotherapy use were statistically significant for 5-year
OS. Sex, RT and type of chemotherapy were not sta-
tistically significant (Table 3). At multivariate analysis:
size, age and chemotherapy were statistically significant
prognostic factors (Table 6).3.6. Chemotherapy and radiotherapy choice according to
EMSOS centers
The use of chemotherapy and RT as adjuvant treatment
varied between centres. Some centres administered
chemotherapy in 80e90% of patients and RT in no
more than 20%. In other centres there was a prevalent
use of RT (maximum in 48%) and chemotherapy was
employed only in 30% of patients. Patients treated with
osteosarcoma-type regimens were given less RT
compared to those treated with STS-type regimens
(respectively, 11% and 66.6%).4. Discussion
This study reports the largest cohort of this rare sar-
coma subtype and is notable for management having
been undertaken in specialist centres defined by mem-
bership of EMSOS. While reinforcing information
about the clinical features, it is most valuable in high-
lighting the uncertainties about best management of
ESOS, illustrated by the variation in use of different
treatment modalities between centres. The data pre-
sented about a potential value for adjuvant chemo-
therapy is stimulating but should be considered with
caution.
The major limitations of the study are that it is
retrospective and the heterogeneity in treatment strategyobserved between participating centres. That said, to
gather adequate amount of data on such a rare disease
would not have been possible without a multicenter
effort carried out by several referral centres throughout
Europe.
In this cohort of ESOS, as seen in other studies
with a population of similar age, 5-year DFS is less
than 50% (47%) compared to that of about 60e65%
[17,18] in localised skeletal osteosarcoma patients
under 40 years. A previous EMSOS study on 481
patients older than 40 years with localised skeletal
osteosarcoma by Grimer [19] reported a 5-year OS of
46% similar to the 5-year OS of 51.4% reported in this
study.
Although ESOS is classified as a soft tissue sarcoma
there is a significant trend of greater responsiveness to
osteosarcoma-type chemotherapy (methotrexate,
cisplatin, doxorubicin, ifosfamide) compared to only
anthracycline-based  ifosfamide chemotherapy as
usually employed in soft tissue sarcoma. Other papers
[5,20,21] have reported response to regimens including
cisplatin. A recent study on 55 patients with ESOS re-
ported an advantage in OS and progression free survival
for patients who received chemotherapy including
cisplatin versus those treated without cisplatin [20].
Another study on 17 patients from the Cooperative
Osteosarcoma Study Group (COSS) reported a
favourable 3- and 5-year estimated DFS of 77% after
multimodal treatment including osteosarcoma-type
chemotherapy (doxorubicin, cisplatin, ifosfamide,
methotrexate) [21].
RT was administered in a small group of patients,
about one third (80/211). It was mainly adjuvant, and
used more frequently in patients with R1 margins and
in those who received STS-type chemotherapy. There
was no difference in the choice of RT administration
according to age, size of primary tumour. Notably,
RT seems to give an advantage in those patients with
tumour >5 cm and R0 margins, whereas no benefit
was seen in patients with R1 margins confirming that
inadequate surgery cannot be overcome by RT. It
seems that those centres which treated ESOS as a soft
tissue sarcoma were more likely to use RT compared
to those who treated ESOS with osteosarcoma-type
chemotherapy. In this series adjuvant chemotherapy
was a positive prognostic factor for both OS and DFS.
The positive trend for an osteosarcoma-type chemo-
therapy regimen was observed for DFS but not for OS.
For patients with localised ESOS, complete surgical
resection is necessary. The role of adjuvant RT and
chemotherapy remains unclear from this study and ar-
gues for prospective randomised allocation but such a
study is likely to prove impossible to conduct. In the
meantime, selection of patients for multiagent chemo-
therapy and RT should be strongly considered, prefer-
ably by multidisciplinary teams working in specialist
referral centres.
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